This series examines how racism affects the prevention, treatment, and delivery of care to minority communities, and to what extent we have adequately incorporated a culture of equity in all phases of our work and our personal lives. To this end, The Oncologist has invited the submission of papers on a broad spectrum of topics, from disparities in outcomes, to the recruitment and training of minority cancer physicians and scientists, to the personal experiences of minority professionals as they practice cancer medicine and pursue careers in the academic community.
The Oncologist family is saddened by the death of oncology pioneer and Pinedo Cancer Care Prize winner José Baselga. You can read Dr. Bruce A. Chabner's "Remembering José" in our journal.
Dr. Cortellini’s work in risks of immunotherapy treatment for patients with pre‐existing autoimmune disease earns him The Oncologist’sYoung Investigator Award. Read more about Dr. Cortellini and his research.
Richard S.P. Huang, et al., The Oncologist
This article reports the current landscape of biomarkers in breast cancer, focusing on patients using comprehensive genomic profiling and PD‐L1 immunohistochemistry in addition to the previous standard of care diagnostics for hormone receptor and human epidermal receptor 2 identification. The relationship between different immunotherapy biomarkers in patients with triple‐negative breast cancer is examined.
Mohammad Jahanzeb, et al., The Oncologist
Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.
Saptaparni Ghosh, et al., The Oncologist
Currently, there are no guidelines for chemotherapy administration in hepatitis C virus-positive patients with breast cancer. This article addresses the knowledge gap, comparing breast cancer patients with and without concurrent hepatitis C virus to determine level of tolerance to treatment.
ALK -Rearranged Non‐Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling
Malinda Itchins, et al., The Oncologist
This report underscores the importance of genetic analysis of serial biopsies to capture the dynamic therapeutic vulnerabilities within a patient’s tumor, while providing a perspective on the complexity of ALK tyrosine kinase inhibitor treatment sequencing.
Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
Mojun Zhu, et al., The Oncologist
This article describes a patient with high-grade pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to Lutetium-177-Dotatate and summarizes the current state of clinical management of high-grade neuroendocrine tumors.
Bruce A. Chabner, MD Editor-in-Chief
What are the prospects for dealing with COVID‐19 more effectively in the future? This editorial addresses the question from the perspective of long‐term control of coronavirus infection.